Skip to main content
Erschienen in: Clinical & Experimental Metastasis 5/2016

03.05.2016 | Research Paper

MicroRNA-106a functions as an oncogene in human gastric cancer and contributes to proliferation and metastasis in vitro and in vivo

verfasst von: Meng Zhu, Ning Zhang, Shuixiang He, Ruirui Yan, Jun Zhang

Erschienen in: Clinical & Experimental Metastasis | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Abstract

Mounting evidences has shown that miRNAs are involved in the development and progression of gastric cancer acts as tumor suppressor genes or oncogenes. In our previous studies, we have found that the up-regulation of miR-106a occurs frequently in human gastric cancer tissues compared with that of normal tissues. Here, we investigate the role of the ectopic expressed miR-106a in the progression and metastasis of gastric cancer in vitro and in vivo. FFPE samples have the priority to be included and qRT-PCR was used to detect the miR-106a expression. Human gastric cancer cells and immortalized gastric epithelial cell were selected and the miR-106a mimic and inhibitor were transfected. Cell growth was determined by MTT method. The flow cytometric analysis for cell apoptosis and transwell assays for evaluating the cell migration and invasion were conducted. Luciferase assay and western blot confirmed the direct binding site of miR-106a and its target. BALB/c nude mice were randomly divided to explore the implantation of gastric cancer cells transfected with miR-106a antagomir. Abnormal over-expression of miR-106a significantly promoted gastric cancer cell proliferation, metastasis, inhibited the cell apoptosis. Functional experiment ascertained that miR-106a interacted with FAS and mediated caspase3 pathway. Knockdown of miR-106a leaded to the attenuation of gastric cancer implantation capacity in vivo. Moreover, expression of TIMP2 was inversely associated with miR-106a in nodule tissues. Apoptotic body was also seen under electron microscope accompanied by silencing of miR-106a. Together, this data indicated that miR-106a may act as an oncogene and contribute to gastric cancer development.
Literatur
3.
Zurück zum Zitat Piazuelo MB, Correa P (2013) Gastric cancer: overview. Colomb Med 44(3):192–201PubMed Piazuelo MB, Correa P (2013) Gastric cancer: overview. Colomb Med 44(3):192–201PubMed
10.
Zurück zum Zitat Wang Z, Wang B, Shi Y, Xu C, Xiao HL, Ma LN, Xu SL, Yang L, Wang QL, Dang WQ, Cui W, Yu SC, Ping YF, Cui YH, Kung HF, Qian C, Zhang X, Bian XW (2014) Oncogenic miR-20a and miR-106a enhance the invasiveness of human glioma stem cells by directly targeting TIMP-2. Oncogene. doi:10.1038/onc.2014.75 Wang Z, Wang B, Shi Y, Xu C, Xiao HL, Ma LN, Xu SL, Yang L, Wang QL, Dang WQ, Cui W, Yu SC, Ping YF, Cui YH, Kung HF, Qian C, Zhang X, Bian XW (2014) Oncogenic miR-20a and miR-106a enhance the invasiveness of human glioma stem cells by directly targeting TIMP-2. Oncogene. doi:10.​1038/​onc.​2014.​75
12.
Zurück zum Zitat Yue B, Sun B, Liu C, Zhao S, Zhang D, Yu F, Yan D (2015) Long non-coding RNA Fer-1-like protein 4 suppresses oncogenesis and exhibits prognostic value by associating with miR-106a-5p in colon cancer. Cancer Sci 106(10):1323–1332. doi:10.1111/cas.12759 CrossRefPubMedPubMedCentral Yue B, Sun B, Liu C, Zhao S, Zhang D, Yu F, Yan D (2015) Long non-coding RNA Fer-1-like protein 4 suppresses oncogenesis and exhibits prognostic value by associating with miR-106a-5p in colon cancer. Cancer Sci 106(10):1323–1332. doi:10.​1111/​cas.​12759 CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Zhu M, Zhang N, He S (2014) Similarly up-regulated microRNA-106a in matched formalin-fixed paraffin-embedded and fresh frozen samples and the dynamic changes during gastric carcinogenesis and development. Pathol Res Pract 210(12):909–915. doi:10.1016/j.prp.2014.07.008 CrossRefPubMed Zhu M, Zhang N, He S (2014) Similarly up-regulated microRNA-106a in matched formalin-fixed paraffin-embedded and fresh frozen samples and the dynamic changes during gastric carcinogenesis and development. Pathol Res Pract 210(12):909–915. doi:10.​1016/​j.​prp.​2014.​07.​008 CrossRefPubMed
15.
Zurück zum Zitat Wang Z, Liu M, Zhu H, Zhang W, He S, Hu C, Quan L, Bai J, Xu N (2013) miR-106a is frequently upregulated in gastric cancer and inhibits the extrinsic apoptotic pathway by targeting FAS. Mol Carcinog 52(8):634–646. doi:10.1002/mc.21899 CrossRefPubMed Wang Z, Liu M, Zhu H, Zhang W, He S, Hu C, Quan L, Bai J, Xu N (2013) miR-106a is frequently upregulated in gastric cancer and inhibits the extrinsic apoptotic pathway by targeting FAS. Mol Carcinog 52(8):634–646. doi:10.​1002/​mc.​21899 CrossRefPubMed
19.
Zurück zum Zitat Vilmont V, Filhol O, Hesse AM, Coute Y, Hue C, Remy-Tourneur L, Mistou S, Cochet C, Chiocchia G (2015) Modulatory role of the anti-apoptotic protein kinase CK2 in the sub-cellular localization of Fas associated death domain protein (FADD). Biochim Biophys Acta 1853(11 Pt A):2885–2896. doi:10.1016/j.bbamcr.2015.08.001 CrossRefPubMed Vilmont V, Filhol O, Hesse AM, Coute Y, Hue C, Remy-Tourneur L, Mistou S, Cochet C, Chiocchia G (2015) Modulatory role of the anti-apoptotic protein kinase CK2 in the sub-cellular localization of Fas associated death domain protein (FADD). Biochim Biophys Acta 1853(11 Pt A):2885–2896. doi:10.​1016/​j.​bbamcr.​2015.​08.​001 CrossRefPubMed
23.
Zurück zum Zitat Moon YW, Jeung HC, Rha SY, Yoo NC, Roh JK, Noh SH, Kim BS, Chung HC (2007) Changing patterns of prognosticators during 15-year follow-up of advanced gastric cancer after radical gastrectomy and adjuvant chemotherapy: a 15-year follow-up study at a single korean institute. Ann Surg Oncol 14(10):2730–2737. doi:10.1245/s10434-007-9479-4 CrossRefPubMed Moon YW, Jeung HC, Rha SY, Yoo NC, Roh JK, Noh SH, Kim BS, Chung HC (2007) Changing patterns of prognosticators during 15-year follow-up of advanced gastric cancer after radical gastrectomy and adjuvant chemotherapy: a 15-year follow-up study at a single korean institute. Ann Surg Oncol 14(10):2730–2737. doi:10.​1245/​s10434-007-9479-4 CrossRefPubMed
26.
Zurück zum Zitat Goseki N, Takizawa T, Koike M (1992) Differences in the mode of the extension of gastric cancer classified by histological type: new histological classification of gastric carcinoma. Gut 33(5):606–612CrossRefPubMedPubMedCentral Goseki N, Takizawa T, Koike M (1992) Differences in the mode of the extension of gastric cancer classified by histological type: new histological classification of gastric carcinoma. Gut 33(5):606–612CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Roviello F, Marrelli D, de Manzoni G, Morgagni P, Di Leo A, Saragoni L, De Stefano A (2003) Prospective study of peritoneal recurrence after curative surgery for gastric cancer. Br J Surg 90(9):1113–1119. doi:10.1002/bjs.4164 CrossRefPubMed Roviello F, Marrelli D, de Manzoni G, Morgagni P, Di Leo A, Saragoni L, De Stefano A (2003) Prospective study of peritoneal recurrence after curative surgery for gastric cancer. Br J Surg 90(9):1113–1119. doi:10.​1002/​bjs.​4164 CrossRefPubMed
29.
Zurück zum Zitat Liotta LA, Stetler-Stevenson WG (1991) Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res 51(18 Suppl):5054s–5059sPubMed Liotta LA, Stetler-Stevenson WG (1991) Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res 51(18 Suppl):5054s–5059sPubMed
Metadaten
Titel
MicroRNA-106a functions as an oncogene in human gastric cancer and contributes to proliferation and metastasis in vitro and in vivo
verfasst von
Meng Zhu
Ning Zhang
Shuixiang He
Ruirui Yan
Jun Zhang
Publikationsdatum
03.05.2016
Verlag
Springer Netherlands
Erschienen in
Clinical & Experimental Metastasis / Ausgabe 5/2016
Print ISSN: 0262-0898
Elektronische ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-016-9795-9

Weitere Artikel der Ausgabe 5/2016

Clinical & Experimental Metastasis 5/2016 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.